MPFS Final Rule Decreases Conversion Factor for 2027
CMS finalized the 2027 Medicare Physician Fee Schedule, including conversion factor reductions and QPP policy updates.
Read moreThe U.S. Departments of the Treasury, Labor, and Health and Human Services issued a new proposed rule Oct. 27, that outlines policies related to the No Surprises Act (NSA) independent dispute resolution (IDR) process. The rule addresses disclosure of claim eligibility information by insurers, communication during the open negotiation period, collection of administrative fees and batching multiple claims into a single IDR dispute.
On initial review of the proposed rule, the departments appear to address the concerns raised by the American College of Radiology® (ACR®) with regard to lack of communication about claim eligibility, IDR backlogs and access to the IDR process for low-cost claims, including batching requirements. The government proposes to expand batching to allow multiple codes from a single patient encounter. In addition, the departments propose to allow batching by groupings of Current Procedural Terminology® (CPT®) codes, rather than single CPT codes. These are positive changes, but ACR remains concerned about other proposals, including limiting batching to 25 line items in a single dispute.
ACR continues to review the details of this proposed rule and will provide a detailed summary. For more information or if you have questions, contact Katie Keysor, ACR Senior Director of Economic Policy.
MPFS Final Rule Decreases Conversion Factor for 2027
CMS finalized the 2027 Medicare Physician Fee Schedule, including conversion factor reductions and QPP policy updates.
Read moreCMS Finalizes Site-Neutral Payments for Non-Contrast Imaging Services in OPPS
ACR outlines key OPPS changes, including site-neutral payments for certain non-contrast imaging services beginning Jan. 1, 2027.
Read moreACR Applauds NRC for Adding IR to Medical Advisory Committee
ACR welcomes a new IR seat on the NRC advisory committee, strengthening expertise for radionuclide therapy, licensing and patient care.
Read more